Recent FDA approvals and therapies under FDA review are adding new treatments to the armamentarium, said Paul Hahn, MD, vitreoretinal surgeon at NJRetina.
Recent FDA approvals and therapies under FDA review are adding new treatments to the armamentarium, said Paul Hahn, MD, vitreoretinal surgeon at NJRetina.
Transcript
In the current ASRS Preferences and Trends survey, were there any novel therapies that respondents were excited about?
Just like technology, this field of retina has been rife with changes in therapies. Over the past year, there was the FDA approval of this sustained delivery surgical implant for wet AMD [age-related macular degeneration]. The response has been kind of mixed, with some being very excited and some being not so excited. Again, I think that the place for this device has yet to be determined, but in my opinion, has an important place in our treatment armamentarium.
Since the survey was actually released, there was the FDA approval of another novel therapeutic agent, a bispecific anti-VEGF [vascular endothelial growth factor] anti–Ang-2 inhibitor—the first of its kind. Retina specialists in the survey were most excited about its potential for extended durability, and certainly, in the next upcoming year’s survey, we'll poll the retina specialists to see what the temperature is and what their utilization is on this new drug.
Perhaps also very exciting, under current FDA review, is the first potential treatment for geographic atrophy and dry macular degeneration. At the time of the survey, results were somewhat mixed, with some retina specialists being enthusiastic about it and some being somewhat lukewarm. Since the survey, some more favorable results have been released, and it would be very interesting to see if that moves the needle. By the time of next year’s survey, we may likely have information as to whether or not this drug is FDA approved, and we'll certainly poll retina specialists to see what their thoughts are on this
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More